Navigation Links
Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
Date:12/20/2007

Summary: Genmab's Partner, Roche has Initiated a Phase II study of R1507

for the Treatment of Sarcoma

COPENHAGEN, Denmark, December 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner, Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma. The R1507 antibody was created by Genmab under the company's agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.

"R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that R1507 may offer an additional treatment option to sarcoma patients."

About Sarcoma

Sarcoma is a cancer of the connective tissue including muscle, bone, fat, nerve, cartilage, blood vessel and deep skin tissue. Due to the wide variety of types of sarcoma, the disease is often difficult to detect, is often misdiagnosed and is complex to treat. Sarcoma is a rare type of cancer with US incidence of approximately 9,000 to 11,000 new cases per year. Of these approximately 8,000 are cases of soft tissue sarcoma and 2,000 are sarcoma of the bone.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); and UniBody(R) are all trademarks of Genmab A/S.


'/>"/>
SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... River Falls, Wisconsin (PRWEB) , ... July 25, 2017 , ... ... solutions for the food and beverage industry, offers Citri-Fi® 125. This natural citrus fiber ... used to thicken and extend real tomato in sauces, condiments and spreads. Today, more ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... and Canada who have proven their superior service quality as rated by hiring ... as an industry leader based on service quality ratings from their placed talent. ...
(Date:7/20/2017)... AUSTIN, TX (PRWEB) , ... July 20, 2017 ... ... platform focused on health-related quality of life, today announced its full advisory board. ... also announced the promotion of James Crooks, PhD, former VP of Engineering, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Crucial ... trial sites and study participants truly unified. TrialKit, a native mobile app, empowers ... Part 11) research studies entirely on mobile devices. With TrialKit, clinical researchers can ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):